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INTERAKSI FARMAKOKINETIK ANTARA PROPRANOLOL DAN Eurycoma 
longifolia (TONGKAT ALI) 
 
ABSTRAK 
Objektif kajian ini adalah untuk menilai kemungkinan interaksi 
farmakokinetik di antara propranolol dan ekstrak herba Tongkat Ali. Kajian 
rawak bersilang  rabun sebelah, melibatkan 14 orang sukarelawan lelaki muda 
yang sihat dan tidak merokok telah dijalankan. Tablet Propranolol 80 mg 
diberikan secara oral bersama-sama dengan i) kapsul placebo (200 mg laktos) 
sebagai kontrol atau ii) 200 mg kapsul Tongkat Ali ekstrak berasaskan air 
(0.0272+0.0026% eurycomanone) sebagai rawatan ujian selepas berpuasa 
semalaman. Sampel darah diambil pada 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 dan 10 jam. 
Tekanan darah dan kadar denyutan nadi diukur sebelum setiap pengambilan 
sampel darah. Kepekatan Propranolol dalam plasma diukur menggunakan 
kaedah HPLC yang telah disahkan dan parameter farmakokinetik (AUC0-∞, Cmax, 
Tmax dan t1/2) dikira menggunakan model bukan kompartmen. Perbezaan dalam 
parameter farmakokinetik di antara kumpulan ujian dan control, dianalisis secara 
statistik dengan menggunakan ujian ANOVA untuk AUC0-∞, Cmax dan t½   dan 
menggunakan  ujian Wilcoxon Signed Ranks untuk Tmax .Perbezaan tekanan 
darah terendah, kadar denyutan nadi dan waktu ianya berlaku, di antara 
kumpulan ujian dan kontrol, dianalisa secara statistik dengan menggunakan 
ANOVA. Keputusan kajian menunjukkan pengurangan yang jelas dalam 
bioavailabiliti propranolol semasa ia diambil bersama-sama dengan ekstrak 
Tongkat Ali, nilai AUC0-∞ dan Cmax Propranolol mengurang secara signifikan 
sebanyak 29% dan 42%( masing-masing nilai p <0.005 dan p <0.002). apabila 
ianya diambil bersama Tongkat Ali. Julat keyakinan 90% untuk nisbah min 
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AUC0-∞ ialah 52% ke 78% dan julat bagi Cmax ialah 44% ke 64%. Julat-julat ini 
adalah di luar julat bioequivalen iaitu 80 – 125%. Tmax menjadi lebih lambat 
dengan kadar 86% (p=0.004). Tiada perbezaan signifikan bagi nilai t1/2 di antara 
kumpulan ujian dan kontrol.  Tujuh subjek sudah mencukupi untuk memberikan 
kuasa kajian 80% bila diambil kira dari Cmax, walau bagaimanapun 14 subjek 
hanya dapat menghasilkan 66% kuasa kajian bila diambil kira dari parameter 
AUC0-∞ . Perbezaan antara tekanan darah terendah  serta kadar nadi dan masa 
ianya berlaku, di antara dua kumpulan berkenaan adalah tidak signifikan secara 
statistik. Berdasarkan kepada keputusan kajian ini, seandainya propranolol 
diambil bersama Tongkat Ali adalah disarankan agar masa pengambilan kedua-
duanya  dijarakkan bagi mengelak kesan interaksi farmakokinetik. Oleh kerana 
kesan ke atas tekanan darah dan kadar denyutan nadi tidak ketara dalam kajian 
dos tunggal, kajian dos berulang dalam  jangka panjang adalah disarankan bagi 
mendapatkan maklumat yang lebih jelas berkaitan interaksi farmakokinetik dan 
farmakodinamik antara Propranolol dan ekstrak Tongkat Ali. 
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A PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND 
Eurycoma longifolia (TONGKAT ALI) 
 
ABSTRACT  
The objective of this study is to evaluate the possible pharmacokinetic 
interaction between propranolol and Tongkat Ali herbal extract. A randomised 
single-blinded crossover study for single dose treatments was conducted in 14 
healthy non-smoker young males. Propranonol (Inderal®) 80 mg tablet was 
orally-administered with i) placebo [200 mg Lactose] as control treatment and 
with ii) 200 mg of water-based extract of Tongkat Ali [0.0272+0.0026% 
eurycomanone] as test treatment following an overnight fasting. Blood samples 
were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 10 hrs. Blood pressure and heart 
rate were measured before each blood sampling. Plasma concentrations of 
propranolol were estimated using a validated HPLC method and the 
pharmacokinetic parameters (AUC0-∞, Cmax, Tmax and t½) were calculated by non-
compartmental model. The differences in the pharmacokinetic parameters 
between control and test treatments were statistically analyzed using ANOVA for 
AUC0-∞, Cmax and t½ and using Wilcoxon Signed Ranks Test for Tmax. The 
differences in the lowest blood pressure and heart rate and their time of 
occurrence between test and control treatments were also statistically analysed 
using ANOVA. The study results demonstrated a decrease in the bioavailability 
of propranolol when it was administered with Tongkat Ali extract, its AUC0-∞ and 
Cmax were significantly decreased by 29% and 42% (p<0.005 and p<0.002 
respectively). The 90% confidence interval of the ratio of the means of AUC0-∞ 
was 52 to 78% and for the Cmax the range was 44 to 64%. These ranges were 
outside the bioequivalence range of 80-125%. Tmax was significantly delayed by 
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86% (p=0.004). The t½ was not significantly different (p >0.1) between the test 
and control treatments.  Seven subjects were sufficient to give 80% power of 
study when calculated from Cmax, however fourteen subjects could only give 
66% power, when calculated from AUC0-∞ parameter. The difference in the 
mean lowest blood pressure and heart rate and their time of occurrence 
between the two study phases was not statistically significant.  Based on the 
results, it is recommended that when the propranolol and Tongkat Ali are 
consumed together, their administrations should be separated to avoid 
pharmacokinetic interaction. Since the effect on blood pressure and heart rate 
were not obvious in single dose study, a long term repeated dose study is 
recommended for further evaluation of both the pharmacokinetic and 
pharmacodynamic interactions between propranolol and Tongkat Ali.  
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Chapter 1 
INTRODUCTION 
1.1 Overview  
           Herbal medicine is the traditional or folk medicine practice based on the 
use of plants or plant extracts. People in all nations have used many kinds of 
herbs for the treatment of ailments since prehistory until now. In the 19th century 
the scientists started with extracting the active ingredients form plants to form 
medicines but over the time and due to the development of chemistry, chemists 
began making their own version of plant compounds. Therefore a transition from 
raw herbal compounds to modern pharmaceutical drug usage occurred with 
subsequent decline in the herbal medicine usage. However recently, people are 
coming back to the herbal medicines. They believe that herbal medicines are 
safe because they are natural.  
 
           Herbal medicines or as it is called nowadays, herbal supplements, tend 
to be a commercial product in the form of tablet or capsule manufactured and 
marketed by the health food or medicinal industries to the general public. Herbal 
supplement is consumed at the same time with pharmaceutical medicines which 
is still the dominant way of treatment but usually without medical control. 
Pharmaceutical medicines can interact with herbal medicines. The likelihood of 
drug-herb interactions could be higher than drug-drug interactions, if only 
because drugs usually contain single chemical entities, while almost all herbal 
medications (even single-herb products) contain mixtures of pharmacologically 
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active constituents such as, essential oils, tannins, coumarins, anthraquinones, 
saponins, glycosides, anthocyanins, alkaloids and flavonoids, all of which may 
potentially participate in drug-herb interactions. This interaction occurs in two 
general ways, pharmacokinetic or pharmacodynamic or both together. The 
popularity of herbal medicinal products makes it important to understand the 
potential interactions between herbs and drugs (Cott, 2001; UMMC, 2000).  
 
            Tongkat Ali (Eurycoma longifolia) is one of the most famous herbs in 
Malaysia and Southeast Asia. This fame came from the wide spectrum of 
pharmacological activities associated with the constituents and crude extracts of 
this plant, especially its aphrodisiac and health-enhancing effect. The roots of 
this plant are used as folk medicine for the treatment of sexual insufficiency (it is 
claimed to increase virility and sexual prowess), persistent fever, malaria, 
aches, dysentery, glandular swelling, and as a health supplement (Jaganath & 
Teik, 2006).   
     
             The consumption of Tongkat Ali is currently done in two ways, the 
traditional way, by soaking the herb or boiling it in water then drink it like tea, or 
the modern way, by taking the manufactured products of Tongkat Ali.  The 
manufactured products could be the extract or the ground powder. They are in 
various types of preparations such as, capsules, soft drinks and tea, coffee or 
cocoa drink mixed with Tongkat Ali. These products are easily available in the 
Malaysian markets as herbal supplements or enriched food products.    
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          Many studies have been conducted on this herb to identify its chemical 
components and to prove its pharmacological activities. To our knowledge, 
there is only one study concerning the pharmacokinetic interaction between a 
pharmaceutical drug and Tongkat Ali herb (Zainah et al., 2005). This study was 
conducted in vitro on rats hepatocytes and indicated that some of the Tongkat 
Ali products have an effects on the liver drug metabolizing enzymes. However, 
the pure compounds of Tongkat Ali did not demonstrate this effect. 
 
 
        From the discussion above, it was therefore important to conduct a study 
on the pharmacokinetic interaction between Tongkat Ali herb and 
pharmaceutical drugs, especially those drugs which patients may combine 
Tongkat Ali with them to overcome their side effects, as with β-Blockers.  
 
 
           Beta-Blockers have been frequently associated with sexual dysfunction, 
particularly impotence and decreased libido. Fogari and Zoppi (2002) mentioned 
that the majority of reports dealing with sexual dysfunction due to β-blockade 
relate to propranolol. Propranolol is a lipophilic β-blocker. It can readily cross the 
blood-brain barrier and increase the tendency toward sedation or depression, 
which in turn may cause loss of libido (Fogari and Zoppi, 2002). So, we have 
decided to study the pharmacokinetic interaction which may occur between 
propranolol and Tongkat Ali when taken concomitantly in vivo.  
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1.2 Objectives of the Study  
1.2.1 General objective 
 The overall objective of conducting this study is to determine a single 
dose pharmacokinetic interaction when propranolol is consumed together with 
the water-base extract of Tongkat Ali in healthy volunteers. 
 
1.2.2 Specific Objectives 
i) To establish an analytical method for measuring propranolol 
concentrations in plasma. 
ii) To conduct pharmacokinetic interaction study between propranolol 
and the water base extract of Tongkat Ali.  
iii) To measure the pharmacokinetic parameters of propranolol when 
taken with placebo and when taken with Tongkat Ali. The 
pharmacokinetic parameters to be measured are the bioavailability 
parameters i.e area under the curve (AUC), maximum plasma 
concentration (Cmax) and the time to reach maximum concentration 
(Tmax) and other pharmacokinetic parameters like terminal half life (t½), 
volume of distribution (Vd) and total body clearance (CL).  
iv) To compare some of the pharmacokinetic parameters (AUC & t½) 
calculated using advanced pharmacokinetic program (WinNon Lin) 
and calculated manually on Excel program.  
v) To compare the pharmacokinetic parameters of propranolol when 
taken with placebo and when taken with Tongkat Ali.  
vi) To correlate the pharmacokinetic results with pharmacodynamic 
changes (Blood Pressure and heart rate) in the volunteers.  
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Chapter 2 
LITERATURE REVIEW 
 
2.1       Analysis Method for Measuring Propranolol Concentrations in 
Plasma. 
     
              To date, various methods have been developed for the determination 
and quantification of propranolol from the biological matrices (serum, plasma, 
blood or urine). In the method developed by El-Saharty, (2003), reversed phase 
high-performance liquid chromatography (RP-HPLC) was used to quantify 
propranolol extracted from the rabbit’s plasma. However, the quantitative 
determination of propranolol was only valid in the concentration range 5 to 200 
μg/ml which was not sensitive enough for clinical pharmacokinetic studies 
where expected propranolol concentrations were in nanograms (mean peak 
plasma concentrations of propranolol is between 15 to 180 ng/ml following the 
usual oral dose of propranolol 80 mg (Katzung, 2001). In another method 
developed by Wren & Tchelitcheff, (2006), ultra-performance liquid 
chromatography linked to a mass spectrometer (UPLC/MS) was used to identify 
propranolol.  This article unfortunately did not provide enough information either 
on the extraction procedures or the quantified concentration of propranolol. 
Furthermore, the usage of UPLC plus MS instrument is an expensive 
combination compared to an HPLC system.  In another method developed by 
Kristoffersen et al., (2006), an automated solid phase extraction (SPE) was 
used to extract propranolol from whole blood samples followed by an RP-HPLC 
coupled with an MS for the determination and quantification of the drug. The 
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use of whole blood samples however, is not recommended as it may lead to 
loss of sensitivity of the column due to the formation of an irreversible binding 
between the macromolecules found in blood (such as proteins) and the surface 
of the backing material. Moreover, this method is expensive because of the 
equipment used (SPE, RP-HPLC and MS) with low recovery of propranolol 
(80%).  
 
In this study, HPLC method of analysis of propranolol from plasma was 
adopted from Rasool et al. (1997) study and Zain-Hamid et al. (1999) study. 
This method can give good recovery (90%), sensitive (upto 9 ng/ml) and the 
cost of the method is reasonable.  
       
2.1.2   Chemical Analysis Using High Pressure Liquid Chromatography 
(HPLC) 
           High performance liquid chromatography (HPLC) is a powerful technique 
of analysis. It can easily achieve separations and analysis of very small 
concentrations, up to fractions of ng/ml of the drugs which have been extracted 
from biological matrix like blood, plasma, serum and urine. This technique of 
analysis is based on the partition coefficient of the analyte between the solid 
stationary phases (column) and the liquid mobile phase. The column usually 
contains many kinds of packings that consist of uniform, porous silica particles 
with spherical or irregular shape. The mobile phase which usually consists of a 
mixture of solvents is pumped through the column under high pressure. The 
function of the mobile phase is to push the injected analyte through the column 
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to be separated. The separated sample will then be detected by many kinds of 
detectors, for example UV detectors, fluorescence detector or photodiode Array 
detector (PDA) (Waters, 2007).  
 
            Photodiode array detector (PDA) can be used to measure and detect 
samples over the entire UV to visible (UV-Vis) spectrum. It is a highly beneficial 
tool in identification and analysis of sample compounds (Jones, 1985). 
 
           The separation process of the HPLC instrument can be done by two 
systems, reversed phase HPLC system and normal phase HPLC system. The 
reversed-phase system is characterized by strong interaction between the 
sample molecules and the polar mobile phase, due to dipole interaction or 
hydrogen bonding of the solvents basicity (proton acceptor) or the solvent 
acidity (proton donor). On the other hand, weak interaction exists between the 
sample molecules and the nonpolar stationary phase. Normal-phase system is 
just the opposite of the reversed-phase system. The interaction is strong 
between the sample molecules and the nonpolar mobile phase but weak with 
the polar stationary phase (Snyder et al., 1988). 
 
2.1.3   Internal Standard 
           Internal standard is a known amount of a compound, different from the 
analyte that is added to the unknown. Signal from analyte is compared with 
signal from the internal standard to find out how much analyte is present. 
Internal standards are especially useful for analyses in which the quantity of 
sample analysed or the instrument response varies slightly from run to run for 
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reasons that are difficult to control. For example, if signal from the internal 
standard increases or decreases by 8.4% because of a change in solvent flow 
rate or sample loss which can occur during sample preparation steps prior to 
analysis, the signal from the analyte usually increases or decreases by the 
same quantity (also 8.4%). As long as a known quantity of the internal standard 
was added to the unknown analyte prior to any manipulations, the ratio of 
internal standard to unknown analyte remains constant because the same 
fraction of each is changing in any operation (Garrett, 1999). 
 
2.1.4   Bioanalytical Method Validation 
 
Published methods of analysis are often modified to suit the 
requirements of the laboratory performing the assay. To use the same methods 
of analysis in another laboratory with different condition, method of analysis has 
to be validated first. To ensure the acceptability of the performance of a 
bioanalytical method, bioanalytical method validation includes all of the 
procedures that demonstrate the reliability and the reproducibility of this method 
is conducted. The fundamental parameters for this validation include accuracy, 
precision, selectivity, sensitivity, reproducibility, and stability (FDA, 2001a).   
 
 
The accuracy of the measurement refers to how close the measured 
value is to the true or accepted value. The precision refers to how close 
together a group of measurements actually are to each other. Accuracy and 
precision are determined using a minimum of five determinations per 
concentration level (excluding blank samples). The mean value should be within 
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±15% of the theoretical value, except at lower limit of quantification (LLOQ), 
where it should not deviate by more than ±20%. The precision around the mean 
value should also not exceed 15% of the coefficient of variation (CV), except for 
lower limit of quantification LLOQ, where it should not exceed 20% of the 
coefficient of variation CV. Recovery of an analyte in an assay is determined by 
the ratio of the detector response obtained from an amount of the analyte added 
to the biological matrix (plasma) and extracted from it, compared to the detector 
response obtained for the true concentration of the pure authentic standard 
(FDA, 2001a). 
The recovery % =   (extracted analyte / unextracted analyte)  x  100 
 
 
         The selectivity of the methods describes the ability of this method to 
quantify the analytes with less interference from each other or with interference 
with other components. The sensitivity of the methods describes the ability of 
this method to detect and/or quantify the lowest concentrations of the analyte. 
The reproducibility of the methods describes the ability of this method to provide 
the same results if it is applied in different laboratories. The stability of the 
analytical method describes the drug stability in the biological matrix and in the 
chemical preparations under different storage conditions and the container 
systems. 
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2.2 Pharmacokinetic 
           Pharmacokinetics is the dynamics of a drug which is concerned with how 
drug is absorbed, distributed, metabolized and excreted from the body 
(Goodman and Gilman, 2001).  When a drug is administered extravascularly 
(orally, intramuscularly, or applied to the skin by transdermal patch), the drug 
molecules has to absorbed first to reach the systemic circulation. When a 
medication administered orally, the drug dosage form must release drug 
molecules via dissolution, and the molecules must pass through the vascular 
layers of gastrointestinal tract, where they enter capillaries. The distribution of 
the drug occurs after drug molecules entered the vascular system. Drug 
molecules will pass from the bloodstream into various tissues and organs, such 
as muscles and heart. The metabolism of the drug is the chemical conversion of 
the drug molecules; usually by an enzymatically mediated reaction, to another 
chemical entity referred to as a metabolite. The metabolite may have the same 
or a different pharmacologic effect as the parent drug or may even cause toxic 
effect. The excretion of the drug is the irreversible removal of a drug from the 
body and commonly occurs through the kidney or biliary tract (Bauer, 2001). 
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2.2.1   Basic Pharmacokinetic Parameters 
           The pharmacokinetic behavior of most drugs can be summarized by the 
following parameters.  
 
2.2.1.1   Bioavailability 
           Bioavailability means the rate and extent to which the active substance or 
therapeutic moiety is absorbed from a pharmaceutical form and becomes available at 
the site of action. Bioavailability means the fraction of the dose that reaches the 
systemic circulation as intact drug (Birkett, 1999). 
          
           The rate of bioavailability depends upon pharmaceutical factors (drug 
formulations) and gastrointestinal absorption factors, metabolism being 
relatively unimportant. On the other hand the extent of bioavailability depends 
on both, the extent of absorption and the extent of metabolism (Smith and 
Aronson, 1984). 
 
 
           Measurement of drug concentrations in blood, plasma, or serum after 
drug administration is the most direct and objective data to determine systemic 
drug bioavailability. By appropriate blood sampling, an accurate description of 
the plasma drug concentration versus time profile of the therapeutic active drug 
substance can be obtained using a validated drug assay (Bauer, 2001). 
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           The plasma concentration versus time curve contains three features of 
interest, the peak height (Cmax) and the time taken to reach the peak (Tmax) are 
measures of the rate of availability and the total area under the curve (AUC) is a 
measure of its extent (Smith and Aronson, 1984). 
 
  
           The peak height Cmax represents the maximum plasma drug 
concentration obtained after the oral administration of the drug. Cmax provides 
indications that the drug is sufficiently systemically absorbed to provide a 
therapeutic response. In addition Cmax provides warning of possible toxic levels 
of drug. Tmax represents the time required to reach that maximum drug 
concentration after the oral administration of the drug.  At Tmax, the rate of drug 
absorption is exactly equals to the rate of drug elimination. Drug absorption still 
continues after Tmax is reached but at a slower rate. When the value of Tmax 
becomes smaller that will indicate less time to reach peak plasma concentration 
but if it is bigger that will indicate more time to reach peak plasma concentration. 
Area under the curve (AUC) represents the total amount of active drug that 
reaches the systemic circulation, (Shargel and Yu, 1999).  
 
 
           There are factors at work which reduce the availability of the drug prior to 
it entering the systemic circulation. Such factors may include, but are not limited   
to poor absorption from the gastrointestinal tract, hepatic first-pass effect and 
degradation of the drug prior to reaching systemic circulation (Shargel and Yu, 
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1999). These factors will be discussed on the sections of pharmacokinetic 
interactions below on page 20.  
 
2.2.1.2 Apparent Volume of Distribution (Vd) 
           Apparent volume of distribution is a measure of the extent of distribution 
of a drug in the body. Volume of Distribution is the fluid volume required to 
contain the drug in the body at the same concentration as in plasma. For the 
single oral dose, volume of distribution is determined by the ratio of the total 
amount of drug in the body (dose) and the plasma drug concentration (AUC) 
and elimination rate constant (Boomer, 2003). 
Vd = Dose/ (AUC X elimination rate constant) 
 
           At any given time after a drug has been absorbed from extravascular 
sites, the serum and the tissue drug concentrations are in equilibrium. The 
serum concentration of drug is equal to the quantity of the amount of drug in the 
body tissues.  Volume of distribution is inversely proportional to the amount of 
the drug in blood, volume of distribution can be very small if the drug is primarily 
contained in the blood (warfarin Vd=5-7 L) or very large if the drug is distributed 
widely in the body (digoxin Vd=500 L) and is mostly bound to the tissues 
(Bauer, 2001). 
 
           This parameter (Vd) is helpful to measure the dose required to produce a 
given concentration of the drug in plasma at steady (Beers and Berkow, 2005), 
Steady state is the condition in which the amount of drug eliminated at each 
dose interval equals the dose for that interval (Shargel and Yu, 1999). If 
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maintenance dose is just started, it will take some time for the drug to 
accumulate to steady state. To get close to steady state more quickly, a loading 
dose is often used and the volume of distribution is the determinant of the size 
of the loading dose (Birkett, 1999). 
Loading dose = Vd X target plasma concentration 
The volume of distribution is influenced by some factors like plasma protein 
binding and by the lipophilicity of the drug, as explained in section 2.1.1.2.1.   
 
2.2.1.2.1 Plasma Protein Binding  
           Plasma protein binding is the situation when drugs bind to the circulating 
plasma proteins. Since these proteins are large molecules, drugs that are bound 
to proteins cannot pass out of vascular space. Thus, plasma protein binding has 
the effect of restricting the distribution of drugs. When plasma protein binding 
increases the extent of the drug distributed in the body will decrease. Only 
unbound drug (free drug) is available for passive diffusion to tissue sites where 
pharmacologic effects occur. Therefore, the unbound drug concentration may 
be more closely related to drug concentration at the active site and to drug 
effects. However, it is important to remember that binding of drugs to plasma 
proteins is a dynamic equilibrium between the bound and the unbound drug and 
the rates of drug binding and release are very fast, occurring in millisecond 
range (Beers and Berkow, 2005). 
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           In lipophilic or basic drugs, the unbound (or free) drug is able to cross the 
biological membranes easily and the drug may exhibit an extensive volume of 
distribution, despite of its high degree of protein binding. In this way, a drug with 
a very low free fraction (i.e., a high degree of plasma protein binding) can 
exhibit a large volume of distribution. For example, the volumes of distribution of 
imipramine, nortriptyline and propranolol are 1600 + 600, 1300 + 300 and 270 + 
40 liters respectively and their percentages of plasma protein bindings are 90.1 
%, 92 % and 90 % (Shargel and Yu, 1999). 
 
2.2.1.3 Clearance (CL) 
           Clearance is defined as the volume of blood cleared of drug per unit time 
and the units are liter per hour or milliliter per minute. Drugs are cleared by 
various organs in the body. Kidneys and liver are the most common organs 
involved in excretion and metabolism of the drug. For any organ, clearance may 
be defined as the fraction of blood volume containing drug that flows through 
the organ and gets eliminated of the drug per unit time. From this definition 
clearance depends upon the blood flow rate and the ability of the organ to 
eliminate the drug. Clearance can be referred to as the total body clearance, 
which is the sum of all the different clearance processes occurring for a given 
drug by the total body organs. Total body clearance may be defined as the rate 
of drug elimination divided by the plasma drug concentration (Shargel and Yu, 
1999). Total body clearance of a single dose of the drug can be calculated from 
the administered dose and the plasma drug concentration (AUC) (Birkett, 1999).                     
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 Total body Clearance (L / hour) = dose/AUC 
 
           Clearance describes the efficiency of irreversible elimination of the drug 
from the body. When a drug is metabolized, the parent drug will then be cleared 
or eliminated, even if the metabolites of the drug are still in the body but they 
are different chemical entities.  Also the uptake of the drug into the tissues is not 
considered clearance if the unchanged drug eventually comes back out of the 
tissue, however slowly this occurs.  
 
           Clearance is an important parameter because it is used for the 
determination of the maintenance dose rate required to achieve a target plasma 
concentration (Birkett, 1999).  
At steady state: Elimination rate = maintenance dose rate  
 
           The extraction rate of a drug from the blood by an eliminating organ, 
such as the liver, cannot exceed the rate of drug delivery to the organ. Thus, 
clearance has an upper limit, based on drug delivery and hence on blood flow to 
the organ. Furthermore, when the eliminating organ is the liver or gut wall and a 
drug is given orally, part of the dose may be metabolized as it passes through 
the tissues to the systemic circulation; this process is called first-pass 
metabolism. Thus, if extraction (clearance) of a drug is high in the liver or gut 
wall, oral bioavailability is low, sometimes precluding oral administration or 
requiring an oral dose much larger than an equivalent parenteral dose. Drugs 
with extensive first-pass metabolism include propranolol, hydralazine, 
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isoproterenol, lidocaine, meperidine, morphine, nifedipine, nitroglycerin, 
alprenolol, testosterone, and verapamil (Beers and Berkow, 2005). 
 
2.2.1.3.1 Elimination Rate Constant (kel)   
             Elimination rate constant is the first order rate constant describing drug 
elimination from the body. This is an overall elimination rate constant describing 
removal of the drug by all elimination processes including excretion and 
metabolism. The elimination rate constant is the proportionality constant relating 
the rate of elimination of the drug and the amount of drug which remains to be 
eliminated (Birkett, 1999).                                                                           
kel= ln(Cp1) – ln(Cp2) / (t2- t1) 
 
2.2.1.3.2 Half-Life (t1/2)                                                                                   
           Half-life is the time taken for the amount of the drug in the body or the 
plasma concentration to fall by half. Half-life is determined by both volume of 
distribution and clearance, and is increased by an increase in volume of 
distribution (Vd) or by a decrease in clearance (CL).  
   t1/2 = 0.693 X Vd / CL 
           When the ratio of clearance and volume of distribution is constant 
(CL/Vd= kel), half-life is a reciprocal function of the elimination rate constant 
(Shargel and Yu, 1999).                                                                                                              
t1/2 = 0.693 / kel 
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           Half-life concept is applied to the drugs which are cleared from the body 
(eliminated and/or metabolized) by a fixed rate. This means that the amount 
eliminated is proportional to the amount available to be eliminated. 
Mathematically this is known as a first order kinetic, most drugs are in this 
category. This is in contrast to zero order kinetic in which a fixed amount of the 
drug is eliminated per unit time. Thus, the amount cleared is independent of the 
amount to be cleared. Drugs such as acetyl salicylic acid, ethanol and phenytoin 
are primary examples in this category (Shargel and Yu, 1999; Bateman and 
Eddleston, 2006). 
 
2.2.1.3.2.1 Importance of Half-Life 
i)           The time required to reach steady state  
           With chronic dosing, the time required to reach steady state can take 
many half-lives to reach the target plasma concentration. If the drug is given at 
every half-life, half the first dose is eliminated over the first dosing interval. 
Therefore, after the second dose there are 1.5 doses in the body and half of this 
amount is eliminated before the third dose. The drug continues to accumulate 
with continued dosing until there is double the dose in the body, at which point 
the equivalent of one dose is eliminated at each dosing interval (half-life). The 
accumulation of the drug to reach steady state is a mirror image of the 
elimination when dosing is stopped. It takes approximately 5 half-lives to reach 
or to eliminate 97% of the drug concentration (Birkett, 1999). 
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           Dosing interval is the interval between maximum concentration and 
minimum concentration which is just before the next dose. With steady state 
dosing, the extent to which the plasma concentration fluctuate over dosing 
interval is determined by the half-life of the drug and the time between the 
doses. Fluctuations will be greatest when the interval in relation to the half-life of 
the drug is increased and will be smallest when the dosing interval is 
decreased. The degree of fluctuation can be expressed as the ratio of the 
maximum concentration to the minimum concentration (Birkett, 1999).  
 
           In addition to the above, during oral dosing, the degree of fluctuation over 
the dosage interval is also determined by the extent and rate of absorption. The 
slower the absorption of the oral doses the smoother the plasma concentration 
profile so that the fluctuation over the dosing interval is less. And the decrease 
or increase in bioavailability will reflect on the required dose of each interval to 
reach steady state (Birkett, 1999). 
 
ii)           Therapeutic index of drugs  
Therapeutic index of drugs is the ratio of the mean toxic to the mean 
effective dose. Therapeutic index plays an important role in determining its 
optimal dose regimen. Theoretically, a drug level has to stay above the 
minimum therapeutic concentrations as long as possible and sufficiently below 
the toxic dose to avoid an unacceptable frequency of adverse effects. For most 
drugs, this can be achieved quite simply by giving the dosage once every half-
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life such that the maximal variation, peak to trough, is less than 2-fold. However, 
for drugs with high therapeutic indices, it may be more convenient to give a 
much higher dosage of the drug and less frequently. The rational of this type of 
dosing system is when the risk of toxicity is remote. A sufficiently high dose can 
be given to keep drug concentrations above minimum effective levels even at 
the end of the dosing interval, more than one half-live out from the dose. For 
example, Penicillin G (t1/2 = 0.7 hrs) is given every 4-6 hours. Alternatively, if 
therapeutic index is low, the drug may have to be given at lower dosages and 
more frequently than every half-life in order to reduce peak to trough variations 
(Birkett, 1999).  
 
iii)          Drug duration of action after single dose administration   
         The duration of action (teff) is a pharmacodynamic parameter which is 
proportional to half-life. The longer the half-life, the longer the plasma 
concentration will stay in the effective range (Ceff). However, the duration of 
action is a logarithmic, not a linear function of the dose (D0) so that increasing 
the dose is an inefficient way of increasing the duration of action. A simple rule 
of thumb is that doubling the dose increases the duration of action by one half-
life (Shargel and Yu, 1999).      
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2.3 Pharmacokinetic Interactions  
           Pharmacokinetic interactions can occur between drug with another drug, 
with herbs or with food. This interaction result in alterations of drug absorption, 
distribution, metabolism, or excretion. Pharmacokinetic interactions are often 
associated with significant changes in a drug’s plasma concentrations, area 
under the curve, Cmax, Tmax, half-life or clearance and volume of distribution. 
These interactions affect the drug by quantitative alterations, either increasing 
or decreasing the amount of drug available to have an effect. To determine this 
quantitative alteration, bioavailability of the drug has to be measured (Leucuta 
and Vlase, 2006). 
 
2.3.1 Absorption 
         In oral administration, drug absorption occurs predominantly in the small 
intestine. In humans, the mucosa of the small intestine has a large surface area 
which is increased greatly by the folds of villi, and microvilli because of the large 
surface area provided by epithelial folding and the villous structures of the 
absorptive cells. Drug absorption occurs by either passive or active transport, 
with most drugs being absorbed by passive transport. This process involves 
diffusion of a drug from areas with a high drug concentration to regions with 
lower drug concentration by either transcellular or paracellular transport, or a 
combination of both. For transcellular transport, drugs are transported into and 
through the epithelial cells, and then into the blood circulation, whereas for 
paracellular transport, drugs reach the blood circulation via the tight junctions 
between epithelial cells. Only those drugs that are absorbed via the 
 
22
transcellular, but not the paracellular, pathway are subjected to intestinal first-
pass metabolism. The relative contribution of the transcellular and paracellular 
pathway to overall absorption is highly dependent on the lipophilicity of the 
drugs. In vitro studies with Caco-2 cells,  a model of cell culture system which is 
used to study the intestinal permeability in vitro, revealed that the relative 
contribution of the transcellular pathway was 25%, 45%, 85%, and 99% for 
chlorothiazide, furosemide, cimetidine, and propranolol, respectively. These 
values correlated well with the lipophilicity of the compounds (Lin et al., 1999; 
Oulianova et.al., 2006). 
 
           Active transport involves the movement of drugs (i.e., ionized and water-
soluble molecules) against a concentration gradient (i.e., from regions of low 
concentration to areas of high concentration) and therefore requires an energy 
source. Drug absorption that occurs by active transport is usually more rapid 
than that which occurs by passive diffusion. The nonionized form of a drug is 
lipid soluble and readily diffuses across the cell membrane, while the ionized 
form of the drug is lipid insoluble and nondiffusible (Shargel and Yu, 1999). 
 
2.3.1.1 Factors Which Affect Drug Absorption and Bioavailability  
           There are many factors that affect the rate and extent of drug absorption 
and bioavailability, these factors are described below. 
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2.3.1.1.1 Effect of Food on Gastrointestinal Drug Absorption  
           The volume of food, type of meals and even the temperature of food and 
beverages are factors that influence gastrointestinal drug absorption and reduce 
the gastric empting. The larger starting volume of food, the greater the initial 
rate of emptying. After this initial time, the larger the volume the slower the rate 
of emptying. The consumption of fatty meals is the potent inducers of 
cholecytokinin hormone. This hormone leads to retention of the fatty meal in the 
stomach. Carbohydrate and amino acids can also delay gastric emptying, as a 
result of osmotic pressure (Shargel and Yu, 1999; Mason, 2002). 
 
          When drugs are taken with food, there is usually a second peak. This 
corresponds to the delivery of the drug in to the intestine with food, since food is 
not delivered in one delivery. The height and the duration of this peak depend 
on gastrointestinal transit time, when drug is taken with water alone there is only 
one peak in plasma concentration (Mason, 2002).  
 
          The presence of food in gastric lumen stimulates the flow of bile. Bile 
contains bile acids which are surfactants involved in the degradation and 
solubility of fats and increases the solubility of fat-soluble drugs (lipophilic 
drugs). On the other hand the presence of food in the stomach stimulates 
hydrochloric acid secretion, which lowers the pH, causing more rapid dissolution 
of the drugs (Shargel and Yu, 1999).  
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2.3.1.1.2 Perfusion of Gastrointestinal Tract 
           Once the drug is absorbed from the small intestine, it enters the 
mesenteric circulation. Any decrease in mesenteric blood flow will decrease the 
rate of drug removal from intestine thereby reducing the rate of bioavailability. 
There is a role of lymphatic circulation in drug absorption where the drugs are 
absorbed through the lacteal or lymphatic vessels under the microvilli. This way 
of absorption will bypass the first-pass metabolism of the liver because the 
absorption through the hepatic portal vain is avoided. This way may partially be 
responsible for the absorption of some lipophilic drugs (Shargel and Yu, 1999). 
 
2.3.1.1.3 Affect of P-glycoprotein (P-gp) 
           P-glycoprotein is an efflux transporter localized in the apical membrane 
of the intestinal cells, besides other drug eliminating organs. Immunohistological 
studies with human small intestine indicated that P-gp is located on the apical 
brush border membrane of the mature epithelium; therefore, P-gp may play a 
role in limiting the absorption of orally administered drugs by extruding the drugs 
from the epithelial cells into the intestinal lumen (Lin, 2003). 
 
           The cytochromes P450 enzymes (CYP3A4) and P-gp work together to 
co-ordinate an absorption barrier against xenobiotics. P-gp activity can be 
induced by drugs such as clotrimazole, erythromycin, phenobarbital and 
rifampicin, or inhibited by other drugs such as quinidine and verapamil (Adithan, 
2005). 
 
